Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
Thorac Cancer
; 12(8): 1240-1243, 2021 04.
Article
en En
| MEDLINE
| ID: mdl-33624409
Durvalumab is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), leading to an antitumor activity, used as consolidation therapy in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). Several immune-related adverse events (irAEs) have previously been described in patients following treatment with immune checkpoint inhibitors (ICIs). To the best of our knowledge, we report the first case of immunotherapy-induced fully reversible bronchiolitis and bronchiectasis, despite the fact that its pathophysiological mechanism has been previously considered to be irreversible.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Bronquiectasia
/
Bronquiolitis
/
Carcinoma de Pulmón de Células no Pequeñas
/
Antineoplásicos Inmunológicos
/
Neoplasias Pulmonares
/
Anticuerpos Monoclonales
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Thorac Cancer
Año:
2021
Tipo del documento:
Article
País de afiliación:
Francia